Literature DB >> 19818061

ISPOR Health Policy Council proposed Good Research Practices for comparative effectiveness research: benefit or harm?

Til Stürmer, Tim Carey, Charles Poole.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19818061      PMCID： PMC4036452          DOI： 10.1111/j.1524-4733.2009.00653.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  16 in total

1.  Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly.

Authors:  Til Stürmer; Sebastian Schneeweiss; M Alan Brookhart; Kenneth J Rothman; Jerry Avorn; Robert J Glynn
Journal:  Am J Epidemiol       Date:  2005-05-01       Impact factor: 4.897

2.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

Review 3.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

4.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

Review 5.  Immortal time bias in pharmaco-epidemiology.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2007-12-03       Impact factor: 4.897

6.  Some guidelines on guidelines: they should come with expiration dates.

Authors:  Kenneth J Rothman; Charles Poole
Journal:  Epidemiology       Date:  2007-11       Impact factor: 4.822

7.  Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

8.  Guidelines for good pharmacoepidemiology practices (GPP).

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-02       Impact factor: 2.890

9.  The need for randomization in the study of intended effects.

Authors:  O S Miettinen
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

10.  Post-marketing studies of drug efficacy: how?

Authors:  B L Strom; O S Miettinen; K L Melmon
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.